• DOT1L, STING, and Lenalidomide in Myeloma

  2026-10-07

  A 2025 Cancer Letters study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and links its inhibition to DNA damage-associated STING signaling, type I interferon responses, and HLA class II induction. The findings provide a mechanistic rationale for combining DOT1L inhibition with lenalidomide, while remaining preclinical and requiring validation beyond the reported models.

• Ridaforolimus and Senescence Research: Evidence Review

  2026-10-07

  Ridaforolimus, also called Deforolimus or MK-8669, is a research compound described as a selective mTOR inhibitor with reported antiproliferative and anti-angiogenic activity. This overview compares those supplier-reported findings with the published machine-learning senolytic study by Smer-Barreto and colleagues, emphasizing what is established, what remains hypothetical, and where the evidence cannot support broader conclusions.

• EGCG Nanoparticles Enhance FLASH-RT Antitumor Effects

  2026-10-06

  Xu et al. report that functionalized, self-assembled epigallocatechin gallate nanoparticles, termed BENPs, can increase tumor-cell damage and immune activation during FLASH radiotherapy in preclinical models. The study is notable because it addresses the efficacy gap in FLASH-RT through biochemical radiosensitization, while its findings remain limited by model scope, short-term safety measures, and the absence of clinical validation.

• Ibrexafungerp: From Mechanism to Translation

  2026-10-06

  Ibrexafungerp, also known as MK 3118, illustrates how mechanism, environmental context, and resistance biology can be integrated into a translational antifungal strategy. Evidence from Candida isolates supports activity in acidic conditions, while important boundaries remain between in vitro susceptibility, animal models, and clinical decision-making.

• Masitinib (AB1010): Product Overview

  2026-10-05

  Masitinib (AB1010), SKU A2942, is a supplier-described phenylaminothiazole-type tyrosine kinase inhibitor associated with KIT, PDGFRα, PDGFRβ, mast-cell biology, and cancer research. No matched paper evidence was available for this overview.

• Acetylation Biomarkers in Osteoarthritis: Study Analysis

  2026-10-05

  Li et al. integrate transcriptomic datasets, co-expression analysis, machine learning, immune-infiltration estimates, and molecular validation to identify JUN and MYC as acetylation-related osteoarthritis biomarkers. The findings are promising for hypothesis generation, but the diagnostic model and mechanistic interpretation require broader external and functional validation.

• Lenalidomide and the Epigenetic Logic of Myeloma

  2026-10-04

  Lenalidomide research is moving beyond broad immunomodulation toward biomarker-led combinations. New findings connect DOT1L inhibition, innate immune signaling, and IRF4-MYC suppression, creating a translational framework for evaluating CC-5013 in multiple myeloma research.

• Radicicol: Five Questions on Evidence and Scope

  2026-10-03

  A source-grounded overview of Radicicol as an Hsp90 inhibitor, separating reported mechanisms from interpretation and clarifying what current evidence can—and cannot—support across cancer, adipocyte, inflammation and vaccine research.

• Concanavalin A and Conserved Coronavirus Glycans

  2026-10-02

  Guo and colleagues identify conserved high-mannose N-glycosylation sites near the coronavirus spike S2′ cleavage site as a broad antiviral vulnerability. By combining fusion, pseudovirus, authentic-virus, biochemical, and animal models, the study shows that concanavalin A can obstruct spike activation and reduce hCoV-NL63 disease in vivo.

• CD40–STING–TRAF2 Axis in ESCC B Cells

  2026-10-01

  A 2025 study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-high B cells as a central immune feature. Its mechanistic experiments indicate that CD40 and STING compete for TRAF2, shaping non-canonical NF-κB signaling and IRF4-mediated B-cell activation.

• Sulfur Supply Delays Soybean Nodule Senescence

  2026-10-01

  The reference study identifies sulfur delivery into the soybean symbiosome as a regulatory checkpoint that preserves glutathione-dependent scavenging of reactive nitrogen species and delays nodule senescence. Its genetic, mineral-transport, and biochemical evidence connects SULTR-mediated sulfur supply with sustained symbiotic nitrogen fixation and suggests measurable targets for future nodule stress research.

• MMAE as a Functional Probe of Tumor Plasticity

  2026-09-30

  Monomethyl auristatin E (MMAE) is more than a cytotoxic payload: it can help researchers separate tumor-cell state from microtubule vulnerability. This article translates NPC plasticity research into a rigorous assay and translational framework for MMAE-based cancer therapy studies.

• PAD4-IN-2 TFA: Targeted NET Assay Workflows

  2026-09-30

  PAD4-IN-2 TFA, also known as Compound 5i TFA, helps researchers separate tumor-directed uptake from neutrophil PAD4 biology. This workflow-focused guide covers uptake, H3cit, NET, migration, immune-profiling, and troubleshooting strategies for cancer research.

• Psora 4: From Channel Block to Immune Insight

  2026-09-29

  Psora 4 is a selective Kv1.3 blocker for connecting membrane potential, calcium entry, and effector-memory T-cell behavior. This article goes beyond routine workflows by showing how KCNE4-dependent channel architecture changes pharmacological interpretation and disease-model translation.

• Cediranib: Measuring Antiangiogenic Response

  2026-09-29

  Cediranib and AZD2171 can reveal how VEGFR blockade changes signaling, growth, and cell death. This assay-focused guide shows how to separate target engagement from cytotoxicity for more rigorous cancer research conclusions.

8491 records 1/567 page Next 12345 下5页 Last page